Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 4

13:29 EDT 30th March 2015 | BioPortfolio

Drug Discovery News - Page: 4Twitter RSS

Read the latest Drug Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Drug Discovery.

Search or Follow Our Drug Discovery - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Drug Discovery - Page: 4 News.
You can also follow our Drug Discovery - Page: 4 news stories on Twitter: @DiscoveryDrug

Showing "drug drug discovery discovery" News Articles 76 to 100 of 26,000+

Monday 30th March 2015

Intacct Takes the Pain Out of Healthcare Financial Management and Accounting

SAN JOSE, Calif., March 30, 2015 /PRNewswire/ --As healthcare companies grow, it is challenging to monitor performance and keep financial processes running smoothly using traditional, on-premises financial software – especially managing multiple locations, multiple services, and multiple types of patients. More and more, these organizations are moving their accounting software to the cloud w...

Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer

SAN DIEGO, March 30, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Tom Cannell has joined as Chief Commercial Officer. As the Company prepares for global commercialization of Contrave® /Mysimba™ (naltrexone HCl / bupropion HCl extended release), Cannell will lead all aspects of Orexigen's global commercial strategy, assuming responsibilities p...

Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer

SAN DIEGO, March 30, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today the appointment of George K. Ng to the position of Executive Vice President & Chief Legal Officer.  In this capacity, Mr. Ng will be responsible for all legal, compliance and intellectual property functions. Mr. Ng joins the Company from BioDelivery Sciences International, Inc., where he...

Drinking coffee could undo alcohol's damage to liver

Chuck Bednar for redOrbit.com - @BednarChuck Consuming three alcoholic beverages per day is enough to cause liver cancer, but regularly drinking coffee could offset the effects of the disease, a team of scientists affiliated with the World Cancer Research Fund International revealed last week in a new report. As part of t

Teva Pharma to acquire Auspex Pharma for $3.5 bln

Teva Pharmaceutical Industries (NYSE:TEVA), Israel’s largest drug company, said it would buy U.S. drug developer Auspex Pharmaceuticals (NASDAQ:ASPX) for $3.5 billion in a move to strengthen its position on central nervous system condition trea...

UnitedHealth to buy pharmacy benefits manager Catamaran

The nation's largest health insurer, UnitedHealth, will muscle up in its fight against rising specialty drug costs by spending more than $12 billion to buy pharmacy benefits manager Catamaran Corp.

UnitedHealth bulks up for prescription drug cost battle (Update)

The nation's largest health insurer, UnitedHealth, will muscle up for its fight against rising prescription drug costs by spending more than $12 billion to buy pharmacy benefits manager Catamaran Corp.

18-Year-Old Entrepreneur Secures National Distribution with Europa Sports Products

CINCINNATI, March 30, 2015 /PRNewswire/ -- D's Naturals, makers of the revolutionary "No Cow Bar", has announced today that the company has signed with Europa Sports Products to bring D's Naturals to health and fitness stores, facilities, and food/drug markets throughout the country. Europa Sports is the country's leading distributor of health and fitness products, with seven warehouses strat...

DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study

CUPERTINO, Calif., March 30, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program.  DUR-928 is an endogenous, small-molecule, new chemical entity (NCE) that may have broad applicability in metabolic diseases such as nonalcoho...

Benefit and Compensation Consultants (BCC) Announces Its Medical Plans for Spring Enrollment

ROCHESTER, N.Y., March 30, 2015 /PRNewswire/ -- Benefit and Compensation Consultants (BCC) has announced its medical plans for spring enrollment. Plans are available for individuals, families and small business owners, including Medicare-eligible individuals, residing in New York, New Jersey, or Connecticut. To kick off these plans for spring, for any enrollment through April 15 BCC will waiv...

GenSpera Launches National Investor Relations Program

SAN ANTONIO and NEW YORK, March 30, 2015 /PRNewswire/ -- GenSpera Inc. (OTCQB: GNSZ) announced today the selection of PCG Advisory Group (PCG) to launch a comprehensive investor relations initiative for the oncology-focused drug development company. Led by Jeff Ramson, founder and chief executive officer, the PCG team will also be directed by three senior members: Kirin Smith, COO and managin...

FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir Harvoni or Sovaldi in combination with another Direct Acting Antiviral drug

[03-24-2015] The U.S. Food and Drug Administration (FDA) is warning that serious slowing of the heart rate can occur when the antiarrhythmic drug amiodarone is taken together with either the hepatitis C drug Harvoni (ledipasvir/sofosbuvir) or with So...

China FDA accepts for review WuXi MedImmune's IND for monoclonal antibody

WuXi PharmaTech has announced that the China Food and Drug Administration (CFDA) has accepted to review WuXi MedImmune's investigational new drug (IND) application for new anti-IL6 monoclonal antibody for the treatment of rheumatoid arthritis.

EMA validates Biogen and AbbVie's MAA for Zinbryta to treat multiple sclerosis

The European Medicines Agency (EMA) has validated Biogen and AbbVie's marketing authorisation application (MAA) for Zinbryta (daclizumab high-yield process), an investigational drug, to treat relapsing forms of multiple sclerosis (MS) in the European...

PLEDPHARMA PHASE IIB RESULTS SHOW 43% DROP IN NERVE DAMAGE DURING CHEMOTHERAPY

PLEDPHARMA PRESENTS TOP-LINE RESULTS FROM ITS PHASE IIb STUDY – PLEDOX® REDUCES NERVE DAMAGE IN CONJUNCTION WITH CHEMOTHERAPY BY 43 PER CENT PledPharma AB (publ) today announces top-line results from a randomized double-blind placebo-controlled phase IIb study (PLIANT) with the drug candidate PledOx®. In the study, patients were treated with PledOx® to reduce the risk of si...

Novartis digs deeper into cancer with up to $750 mln Aduro deal

March 30 (Reuters) - Swiss drugmaker Novartis is digging deeper into the world of cancer immunotherapy - one of the hottest areas of drug research - through a tie-up with California-based Aduro Biotech worth up to $750 million.

Columbia Laboratories Acquires Exclusive Worldwide License to a Novel Segmented Intra-vaginal Ring Delivery Technology

BOSTON, March 30, 2015 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a specialty pharmaceutical company focused on the development of therapeutics for women's health, has licensed exclusive worldwide rights to a novel intra-vaginal ring ("IVR") technology for the delivery of one or more pharmaceuticals at different dosages and release rates in a single s...

Notice of Annual Results 2014

Biofrontera AG / Notice of Annual Results 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Biofrontera AG (AIM: B8F), the European biopharmaceutical company, will be announcing its annual results for the twelve months period ending 31 December 2014 on 10 April 2015. There is a conference ca...

Fighting back against superbugs

Antibiotics—and antibiotic resistance—are in the news once again, with announcements by McDonald's and Costco that they will eliminate antibiotics that are important to human medicine from use in the production of some of their meats and the disc...

Adamis gets FDA complete response letter for epinephrine pre-filled syringe NDA

US-based Adamis Pharmaceuticals has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) Epinephrine Injection USP 1:1000 0.3mg pre-filled single dose syringe (PFS) product,...

Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells

The webinar will discuss the first patient-specific induced pluripotent stem cell (iPSC) model of a complex metabolic condition and will demonstrate how it is effective for discovery and testing of new therapeutic strategies. Yorba Linda, CA (PRWEB) March 30, 2015 Developing new treatments for Diabetes Type 2 complications is challenging due to the use of cellular models that recapitulate only so...

Synageva BioPharma Submits Kanuma™ (Sebelipase Alfa) Application For LAL Deficiency In Mexico

LEXINGTON, Mass., March 30, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today the submission to the Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) in Mexico for Kanuma as a treatment for patients with lysosomal acid lipase deficiency (LAL Deficiency),...

Yale University and Novogen Release Data on Cantrixil Mode of Action

SYDNEY, March 30, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ:NVGN) and its subsidiary, CanTx, Inc., and Yale University, on March 27 released pre-clinical data on experimental anti-cancer drug, Cantrixil. The data was presented as an oral presentation by Professor Gil Mor MD PhD of Yale Medical School to the 62nd Annual Scientific Meeting of the Societ...

RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights

MARLBOROUGH, Mass., March 30, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology that address high-unmet medical needs, today reported its financial results for the fourth quarter and year ended December 31, 2014, and provided a busine...

Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group

Novartis International AG / Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Collaboration with Aduro is focused on discovery and development of next generation cancer i...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks